This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Viral Genetics Announces Details Of Corporate Restructuring, Including Name Change, Reverse Stock Split And Increase To Authorized Capital

Viral Genetics, Inc. (Pink Sheets:VRAL) today announced it will change its name to VG Life Sciences, Inc. and implement a 1-for-600 reverse split of its common stock. The name change and the reverse stock split are expected to be become effective on or about November 26, 2012, pending review and acceptance by FINRA. Both the name change and the reverse stock split were approved by a majority of the Company’s shareholders after recommendation by the Board of Directors of the Company. This corporate action and name change followed an earlier increase to authorized common stock of the Company in October 2012 and changes to the terms of the Company’s Series A Preferred Shares in August 2012.

“The Board of Directors took these actions for several important reasons,” said Haig Keledjian, Viral Genetics’ CEO. “The primary reason is the strength of our science and our intellectual property portfolio. We have worked long and hard to build our IP and to begin moving some of the molecules and compounds from our basic science and discovery efforts into clinical trials at prestigious medical institutions. In order to accelerate our movement down this path we are revamping our corporate structure into a more credible format. This new capital structure gives us more credibility with potential business partners, institutional funding sources, and the new executive talent that we are seeking to hire as we move from a basic research-oriented company and develop our capabilities as an operating drug development business.

“The name change reinforces our evolution from a purely R&D focus,” continued Mr. Keledjian. “VG Life Sciences, Inc. more accurately depicts our intellectual property and the business focus which is broader than pharmaceuticals and now reaches into biofuels, agricultural technology and other high-growth industries.

“As a significant shareholder of the Company and someone who has devoted more than 15 years of my life to its success, my intention going forward is to build value on this newly established base,” concluded Mr. Keledjian.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs